Cargando…
Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications
Adverse drug reactions can be unpredictable. However, pharmacogenomic testing can help identify patients who may be more susceptible to the toxic effects of certain drugs. Genetic variations in the dihydropyrimidine dehydrogenase and thymidylate synthase genes have been shown to increase the risk of...
Autores principales: | Baldeo, Candice, Vishnu, Prakash, Mody, Kabir, Kasi, Pashtoon Murtaza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041857/ https://www.ncbi.nlm.nih.gov/pubmed/30013790 http://dx.doi.org/10.1177/2050313X18786405 |
Ejemplares similares
-
Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants
por: Raber, Inbar, et al.
Publicado: (2020) -
Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity
por: Ma, Wen Wee, et al.
Publicado: (2016) -
Feasibility of Integrating Panel-Based Pharmacogenomics Testing for
Chemotherapy and Supportive Care in Patients With Colorectal Cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2019) -
Case report: Uridine triacetate in the management of delayed onset 5-fluorouracil toxicity: A case report and review of literature
por: Jacob, Aasems, et al.
Publicado: (2022) -
Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence
por: Soyano, Aixa E., et al.
Publicado: (2019)